{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T14:31:18Z","timestamp":1681828278803},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00520-017-3797-2","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T17:23:20Z","timestamp":1498670600000},"page":"3715-3721","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy"],"prefix":"10.1007","volume":"25","author":[{"given":"Daniel J.","family":"Przybylski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"issue":"4","key":"3797_CR1","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Disease Society of America. Clin Infect Dis 52(4):e56\u2013e93","journal-title":"Clin Infect Dis"},{"key":"3797_CR2","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2012.0103","volume":"10","author":"MR O\u2019Donnell","year":"2012","unstructured":"O\u2019Donnell MR, Abbound CN, Altman J et al (2012) Acute myeloid leukemia. J Natl Compr Cancer Netw 10:984\u20131021","journal-title":"J Natl Compr Cancer Netw"},{"key":"3797_CR3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/.61.3.377-392.1997","volume":"61","author":"K Drlica","year":"1997","unstructured":"Drlica K, Zhao X (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61:377","journal-title":"Microbiol Mol Biol Rev"},{"key":"3797_CR4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1128\/CMR.2.4.378","volume":"2","author":"JS Wolfson","year":"1989","unstructured":"Wolfson JS, Hooper DC (1989) Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 2:378","journal-title":"Clin Microbiol Rev"},{"key":"3797_CR5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00003495-199957030-00007","volume":"57","author":"JA Barman Balfour","year":"1999","unstructured":"Barman Balfour JA, Wiseman LR (1999) Moxifloxacin. Drugs 57:363","journal-title":"Drugs"},{"issue":"Suppl B","key":"3797_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/43.suppl_2.1","volume":"43","author":"JM Blondeau","year":"1999","unstructured":"Blondeau JM (1999) A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new \u2018respiratory quinolones\u2019. J Antimicrob Chemother 43(Suppl B):1","journal-title":"J Antimicrob Chemother"},{"key":"3797_CR7","unstructured":"Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther. 2000; 42:15"},{"key":"3797_CR8","doi-asserted-by":"publisher","unstructured":"Villafuerte-Gutierrez P, Villalon L, Losa JE, Henriquez-Camacho C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol. 2014; Article ID 986938, 9 pages, 2014. doi: 10.1155\/2014\/986938","DOI":"10.1155\/2014\/986938"},{"key":"3797_CR9","first-page":"CD004386","volume":"1","author":"A Gafter-Gvili","year":"2012","unstructured":"Gafter-Gvili A, Fraser A, Paul M et al (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 1:CD004386","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"3797_CR10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","volume":"353","author":"G Bucaneve","year":"2005","unstructured":"Bucaneve G, Micozzi A, Menichetti F et al (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353(10):977\u2013987","journal-title":"N Engl J Med"},{"key":"3797_CR11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/1471-2334-13-356","volume":"13","author":"M Garnica","year":"2013","unstructured":"Garnica M, Nou\u00e9r SA, Pellegrino FLPC, Moreira BM, Maiolino A, Nucci M (2013) Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infect Dis 13:356","journal-title":"BMC Infect Dis"},{"key":"3797_CR12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10096-007-0397-y","volume":"27","author":"H Imran","year":"2008","unstructured":"Imran H, Tleyjeh IM, Arndt CAS et al (2008) Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 27:53","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12 Pt 1","key":"3797_CR13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","volume":"142","author":"A Gafter-Gvili","year":"2005","unstructured":"Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142(12 Pt 1):979\u2013995. doi: 10.7326\/0003-4819-142-12_Part_1-200506210-00008","journal-title":"Ann Intern Med"},{"key":"3797_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00520-016-3436-3","volume":"25","author":"BR Ganti","year":"2017","unstructured":"Ganti BR, Marini BL, Nagel J, Bixby D, Perissinotti AJ (2017) Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse\/refractory acute myeloid leukemia. Support Care Cancer 25:541\u2013547. doi: 10.1007\/s00520-016-3436-3","journal-title":"Support Care Cancer"},{"key":"3797_CR15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/1471-2334-13-563","volume":"13","author":"FG Rosa De","year":"2013","unstructured":"De Rosa FG, Motta I, Audisio E et al (2013) Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infect Dis 13:563","journal-title":"BMC Infect Dis"},{"issue":"4","key":"3797_CR16","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3109\/10428194.2012.725848","volume":"54","author":"A Shinohara","year":"2013","unstructured":"Shinohara A, Yoshiki Y, Masamoto Y, Hangaishi A, Nannya Y, Kurokawa M (2013) Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies. Leuk Lymphoma 54(4):794\u2013798","journal-title":"Leuk Lymphoma"},{"key":"3797_CR17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dkl320","volume":"58","author":"H Baum von","year":"2006","unstructured":"von Baum H, Sigge A, Bommer A et al (2006) Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemothe 58:891\u2013894","journal-title":"J Antimicrob Chemothe"},{"key":"3797_CR18","first-page":"w13985","volume":"144","author":"B Gerber","year":"2014","unstructured":"Gerber B, Koppel J, Paul M et al (2014) Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: a real-world, retrospective comparative single-centre study. Swiss Med Wkly 144:w13985","journal-title":"Swiss Med Wkly"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-3797-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3797-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3797-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T03:35:07Z","timestamp":1602387307000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-3797-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3797"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-3797-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]}}}